A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

PRIMARY OBJECTIVE: I. Correlate \[18F\]FluorThanatrace (FTT) PET/CT uptake in patients with primary breast cancer compared to PARP1 quantitative immunohistochemistry (IHC) as the tissue reference standard. SECONDARY OBJECTIVES: I. Correlate \[18F\]FluorThanatrace uptake with other measures of PARP-1 activity in tumor tissue samples - quantitative IHC, immunofluorescence (IF) and \[125I\]KX1 autoradiography. II. Determine the ranges of uptake on \[18F\]FluorThanatrace PET/CT imaging across patients with breast cancer undergoing \[18F\]FTT PET/CT. III. Demonstrate the reproducibility of \[18F\]FTT uptake on PET/CT using test-retest imaging. IV. Confirm the safety of \[18F\]FluorThanatrace. OUTLINE: Patients receive \[18F\]FTT intravenously (IV) over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the \[18F\]FTT PET/CT scan patients.